Pentoxifylline and Late Onset Sepsis in Preterm Infants

• Status: Completed
• Trial end date: 2013-06-01
• Target enrollment: 0
• Participant gender: All

Summary

• Hypothesis: The investigators hypothesized that Pentoxifylline has potent anti-inflammatory effect which can augment the antimicrobial effect of antibiotics in treatment of Late onset sepsis (LOS) in preterm infants thus decreasing neonatal mortality and morbidity.

• The purpose of this study: to assess the efficacy and safety of Pentoxifylline as an adjunct to antibiotic therapy on mortality and morbidity of preterm infants with LOS.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abd Elazeez Attala Shabaan
• Treatments: Anti-Bacterial Agents; Antibiotics, Antitubercular; Pentoxifylline

Criteria

Inclusion Criteria:

• Appropriate for gestational age preterm infants with suspected or confirmed late onset sepsis

Exclusion Criteria:

• Preterm infants with major congenital malformations

• Preterm infants with chromosomal anomalies

• Preterm infants with inborn-errors of metabolism

• Preterm infants with congenital infection